Urs B. Hagemann

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe et al. · Clinical Cancer Research · 2019 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

Chiara Berlato, Moddasar N. Khan, Tiziana Schioppa et al. · Journal of Clinical Investigation · 2017 · 108 citations · Full text

Medicine, Immunology, Oncology +17

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Urs B. Hagemann, Christine Ellingsen, Joachim Schuhmacher et al. · Clinical Cancer Research · 2019 · 108 citations

Medicine, Oncology, Pharmacology +17

<i>In Vitro</i> and <i>In Vivo</i> Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Urs B. Hagemann, Katrine Wickstroem, Ellen Wang et al. · Molecular Cancer Therapeutics · 2016 · 80 citations

Medicine, Oncology, Pharmacology +17

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models

Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe et al. · Oncotarget · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17